Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | HPGD | P15428 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | GLA | P06280 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.52 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.50 |
| ▸ | FLT3 | P36888 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL701020 | 0.85 | KDM4E (0.57) | KDM4EALDH1A1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL22620711 | 0.84 | KDM4E (0.56) | KDM4EALDH1A1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL913891 | 0.84 | KDM4E (0.56) | KDM4EALDH1A1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL2205092 | 0.84 | HRH4 (0.56) | KDM4EALDH1A1MAPTHPGDLMNA | |
| SCHEMBL4044123 | 0.83 | CDK1 (0.57) | KDM4EALDH1A1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5622391 | 0.83 | KDM4E (0.55) | KDM4EALDH1A1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL6303402 | 0.83 | KDM4E (0.55) | KDM4EALDH1A1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL5780732 | 0.83 | KDM4E (0.56) | KDM4EALDH1A1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL15904734 | 0.83 | KDM4E (0.55) | KDM4EALDH1A1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL25203298 | 0.82 | KDM4E (0.56) | KDM4EALDH1A1RAB9ASMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113272276-A | N-acyl sulfonamide salt FBPase inhibitor, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2021-08-17 | — | — | CN | claimed |
| CN-111269167-A | N-acyl sulfonamide salt FBPase inhibitor, preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2020-06-12 | — | — | CN | claimed |
| WO-2020114457-A1 | N-ACYL SULFONAMIDE SALT FBPASE INHIBITOR, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF | 中国医学科学院药物研究所 | 2020-06-11 | — | — | WO | claimed |
| EP-2948454-B1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENT & IND RES AN INDIAN REGISTERED BODY INCORPORATED UNDER THE REGISTRATION OF SOCIETI (IN) | 2017-05-31 | — | — | EP | claimed |
| US-9447105-B2 | Triazine compounds and a process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-09-20 | — | — | US | claimed |
| US-20150353566-A1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2015-12-10 | — | — | US | claimed |
| EP-2948454-A1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | Council of Scientific & Industrial Research An Indian registered body incorporated under the Registration of Societies Act (Act XXI of 1860) (IN) | 2015-12-02 | — | — | EP | claimed |
| WO-2014115171-A1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2014-07-31 | — | — | WO | claimed |
| WO-2025067429-A1 | COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2025-04-03 | — | — | WO | disclosed |
| US-20240043436-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | PMV PHARMACEUTICALS, INC. | 2024-02-08 | — | — | US | disclosed |
| WO-2023244672-A1 | 2-(IMIDAZO[1, 2-A]1,8-NAPHTHYRIDIN-8-YL)-1,3,4-OXADIAZOLE DERIVATIVES AS ENHANCERS OF INNATE IMMUNE RESPONSE FOR THE TREATMENT OF VIRAL INFECTIONS | ASSEMBLY BIOSCIENCES, INC. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | PMV PHARMACEUTICALS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| EP-3962909-B1 | NOVEL OXALYL PIPERAZINES ACTIVE AGAINST THE HEPATITIS B VIRUS (HBV) | AICURIS GMBH & CO KG (DE) | 2023-10-04 | — | — | EP | disclosed |
| US-6337344-B1 | ANTICOAGULANTS AND ENZYME INHIBITORS FOR CARDIOVASCULAR DISORDERS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-01-08 | — | — | US | disclosed |
| WO-2001064639-A2 | PDE IV INHIBITING AMIDES, COMPOSITIONS AND PHARMACEUTICAL USE | MERCK FROSST CANADA & CO. (CA) | 2001-09-07 | — | — | WO | disclosed |
| EP-1042287-A1 | INDOLE DERIVATIVES AS INHIBITORS OF FACTOR XA | Aventis Pharma Deutschland GmbH (DE) | 2000-10-11 | — | — | EP | disclosed |
| EP-1003504-A2 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | AstraZeneca UK Limited (GB) | 2000-05-31 | — | — | EP | disclosed |
| WO-1999033800-A1 | INDOLE DERIVATIVES AS INHIBITORS OR FACTOR XA | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-07-08 | — | — | WO | disclosed |
| WO-1999007351-A2 | INDOLE DERIVATIVES AND THEIR USE AS MCP-1 ANTAGONISTS | ZENECA LIMITED (GB) | 1999-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353566-A1 | TRIAZINE COMPOUNDS AND A PROCESS FOR PREPARATION THEREOF | TPH2, IDO2, INMT | KDM4E 862/4885ALDH1A1 2885/4885RAB9A 4448/4885 |
| US-11807644-B2 | Methods and compounds for restoring mutant p53 function | TP53, TP53BP1, HRAS | KDM4E 3311/4885ALDH1A1 1977/4885RAB9A 1930/4885 |
| US-20240043436-A1 | METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION | TP53, TP53BP1, HRAS | KDM4E 3311/4885ALDH1A1 1977/4885RAB9A 1930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.